Valion Bio VBIO

NASDAQ VBIO

$2.20 -0.20 (-8.33%)

At close: Sep 10, 2026 · 4:00 PM EDT

Key Stats

Market Cap298,792.01

P/E-0.03

P/S0.85

Div. Yield0.00

Revenue Growth (1y) (Qtr)-54.65

Add ratio to table…

About

Tivic Health Systems, Inc. is a late stage therapeutics company that harnesses the power of the immune system to improve clinical outcomes and save lives. Its lead product candidate is the Toll like receptor 5 agonist Entolimod™, which is being developed for the prevention and treatment of acute radiation syndrome and for mitigating side effects of medical radiation and chemotherapy. In parallel, the company maintains a bioelectronic medicine program that develops non invasive cervical vagus nerve stimulation devices to modulate autonomic functions in neurologic, cardiac and autoimmune conditions. While it previously commercialized the over the counter sinus device ClearUP, Tivic Health is winding down that consumer health business to focus resources on its biologic and bioelectronic pipelines.

The company currently generates revenue solely from the sale of ClearUP and related accessories, including expedited shipping charges, sold directly to consumers through its own website and through resellers such as Simply Medical, Cardinal Health, Amazon, McKesson, Optum Store, Walmart, Target, Best Buy and FSA/HSA Store. Revenue is net of return reserves and reflects the company’s efforts to liquidate existing inventory before exiting the consumer business. Tivic Health does not anticipate meaningful product sales until it obtains regulatory approval for Entolimod or its bioelectronic candidates and can commercialize those products.

The company operates through the following segments: Biologics Program and Bioelectronic Medicine.

Biologics Program: This segment is advancing the Toll like receptor 5 agonist Entolimod™ for acute radiation syndrome and neutropenia indications, supporting manufacturing validation, preparing a biologics license application for the FDA, and conducting IND enabled Phase 2 oncology studies for Entolimod and the second generation candidate Entolasta.
Bioelectronic Medicine: This segment focuses on proprietary non invasive cervical vagus nerve stimulation technology, having completed feasibility and optimization studies with the Feinstein Institutes for Medical Research, and is preparing intellectual property filings while evaluating further clinical applications in post traumatic stress, cardiac disease, inflammatory conditions and ischemic stroke.

Within the biodefense and medical countermeasure sector, Tivic Health holds a differentiated position through its FDA granted Fast Track and Orphan Drug designations for Entolimod, which few competitors possess for acute radiation syndrome. Its bioelectronic approach leverages patent pending precision stimulation parameters that aim to improve reproducibility and clinical effect compared with earlier non invasive vagus nerve devices, giving it a potential edge in a crowded neuromodulation market.

The company’s customer base for its current ClearUP product includes individual consumers purchasing online and a range of retail and pharmacy partners such as Simply Medical, Cardinal Health, Amazon, Walmart, Target, Best Buy and FSA/HSA Store. For its future biologics, Tivic Health anticipates selling to federal agencies, hospital systems and oncology clinics, while its bioelectronic devices would target physicians, health systems and direct to consumer channels pending regulatory clearance.

Investment Thesis

▲ Bull case

Valion Bio is positioned to capture substantial non-dilutive revenue through U.S. government procurement of Entolimod for the Strategic National Stockpile, a pathway significantly de-risked by the NIAID-funded study protocol under the FDA's Animal Rule that mirrors a previously accepted design. This arrangement not only secures up to $7 million in direct funding for pivotal efficacy studies but also includes NIAID's commitment to co-navigate the FDA submission process, effectively combining financial support with regulatory expertise to accelerate BLA filing. Given Entolimod's unique dual-tissue protection of hematopoietic and gastrointestinal systems—a gap unaddressed by current stockpiled agents like Neupogen or Neulasta—the company addresses a critical unmet need in radiation countermeasures, enhancing its competitiveness for multi-agency procurement from BARDA, the Department of War, and allied governments. The convergence of heightened geopolitical tensions, bipartisan stockpile modernization efforts, and Valion Bio's domestic manufacturing footprint via Velocity Bioworks creates a structural tailwind that could translate into a nine-figure revenue event upon contract award, a catalyst the market may be underestimating given the company's current market capitalization and early-stage perception.
The integration of Velocity Bioworks is evolving beyond a cost-saving measure into a self-sustaining, revenue-generating CDMO platform with strategic advantages in the underserved Phase I and II biologics manufacturing market, exemplified by the exclusive commercial development agreement with LarmorBio for the BioScan-NMR platform. By hosting the first commercial installation of this next-generation NMR system at its San Antonio facility targeted for July 2026, Velocity Bioworks gains first-mover access to differentiated technology, positioning itself as a validation and optimization partner rather than a mere service provider—a model that strengthens as the platform scales and aligns incentives with developers. This initiative builds on prior progress, including the successful 200-fold manufacturing scale-up of Entolimod and ongoing third-party business development discussions, signaling that Velocity Bioworks is advancing toward cash flow positivity through standalone CDMO revenue, which could offset cash burn from drug development and provide operating leverage independent of clinical milestones. The market may be overlooking how this dual-role manufacturing capability—serving both internal pipeline acceleration and external clients—creates a resilient financial foundation that enhances long-term sustainability and reduces reliance on dilutive financing.
Valion Bio's strategic pivot toward oncology supportive care, particularly chemotherapy-induced neutropenia, represents a substantial and de-risked commercial opportunity adjacent to its core ARS program, leveraging the same TLR5 agonist mechanism with broader applicability through Entolasta and existing clinical data. The global neutropenia treatment market exceeds $22 billion and is projected to approach $30 billion by the early 2030s, with Valion Bio targeting physician-sponsored trials in 2026 and Phase IIb readiness as an objective—goals enabled by Velocity Bioworks' ability to compress internal timelines, lower manufacturing costs, and secure supply chain control. Unlike many oncology entrants facing high clinical failure rates, Valion Bio benefits from Entolimod's extensive safety profile, having been administered to approximately 300 human subjects and evaluated in 42 non-human primate studies, with over $140 million already invested in the program, reducing technological and regulatory uncertainty. The company's ability to advance Entolasta in parallel—designed for longevity and immunosenescence indications—further extends the platform's addressable market, creating compounding value from a single mechanistic foundation that the market may not fully appreciate amid focus on near-term ARS milestones.

Valion Bio is positioned to capture substantial non-dilutive revenue through U.S. government procurement of Entolimod for the Strategic National Stockpile, a pathway significantly de-risked by the NIAID-funded study protocol under the FDA's Animal Rule that mirrors a previously accepted design. This arrangement not only secures up to $7 million in direct funding for pivotal efficacy studies but also includes NIAID's commitment to co-navigate the FDA submission process, effectively combining financial support with regulatory expertise to accelerate BLA filing. Given Entolimod's unique dual-tissue protection of hematopoietic and gastrointestinal systems—a gap unaddressed by current stockpiled agents like Neupogen or Neulasta—the company addresses a critical unmet need in radiation countermeasures, enhancing its competitiveness for multi-agency procurement from BARDA, the Department of War, and allied governments. The convergence of heightened geopolitical tensions, bipartisan stockpile modernization efforts, and Valion Bio's domestic manufacturing footprint via Velocity Bioworks creates a structural tailwind that could translate into a nine-figure revenue event upon contract award, a catalyst the market may be underestimating given the company's current market capitalization and early-stage perception.
The integration of Velocity Bioworks is evolving beyond a cost-saving measure into a self-sustaining, revenue-generating CDMO platform with strategic advantages in the underserved Phase I and II biologics manufacturing market, exemplified by the exclusive commercial development agreement with LarmorBio for the BioScan-NMR platform. By hosting the first commercial installation of this next-generation NMR system at its San Antonio facility targeted for July 2026, Velocity Bioworks gains first-mover access to differentiated technology, positioning itself as a validation and optimization partner rather than a mere service provider—a model that strengthens as the platform scales and aligns incentives with developers. This initiative builds on prior progress, including the successful 200-fold manufacturing scale-up of Entolimod and ongoing third-party business development discussions, signaling that Velocity Bioworks is advancing toward cash flow positivity through standalone CDMO revenue, which could offset cash burn from drug development and provide operating leverage independent of clinical milestones. The market may be overlooking how this dual-role manufacturing capability—serving both internal pipeline acceleration and external clients—creates a resilient financial foundation that enhances long-term sustainability and reduces reliance on dilutive financing.
Valion Bio's strategic pivot toward oncology supportive care, particularly chemotherapy-induced neutropenia, represents a substantial and de-risked commercial opportunity adjacent to its core ARS program, leveraging the same TLR5 agonist mechanism with broader applicability through Entolasta and existing clinical data. The global neutropenia treatment market exceeds $22 billion and is projected to approach $30 billion by the early 2030s, with Valion Bio targeting physician-sponsored trials in 2026 and Phase IIb readiness as an objective—goals enabled by Velocity Bioworks' ability to compress internal timelines, lower manufacturing costs, and secure supply chain control. Unlike many oncology entrants facing high clinical failure rates, Valion Bio benefits from Entolimod's extensive safety profile, having been administered to approximately 300 human subjects and evaluated in 42 non-human primate studies, with over $140 million already invested in the program, reducing technological and regulatory uncertainty. The company's ability to advance Entolasta in parallel—designed for longevity and immunosenescence indications—further extends the platform's addressable market, creating compounding value from a single mechanistic foundation that the market may not fully appreciate amid focus on near-term ARS milestones.

▼ Bear case

Despite promising government engagement, Valion Bio remains heavily dependent on uncertain procurement outcomes from U.S. agencies like BARDA and the Department of War, with no guaranteed funding or contract in place for Entolimod's inclusion in the Strategic National Stockpile, exposing the company to significant execution risk if geopolitical priorities shift or competing countermeasures gain favor. While NIAID has funded a specific study protocol under the Animal Rule, this does not equate to a procurement commitment, and the path to BLA approval still hinges on favorable study results, successful tech transfer validation from Velocity Bioworks, and FDA acceptance—all of which carry inherent scientific and regulatory uncertainty. The company's financials underscore this vulnerability: operating expenses rose to $5.6 million in Q1 2026 from $1.4 million year-over-year, driven by Velocity Bioworks integration and rebranding costs, while cash reserves declined to $7.2 million from $12.6 million at year-end 2025, reflecting a burn rate that may not be sustainable without near-term non-dilutive inflows or additional financing. Without a secured government contract or meaningful CDMO revenue to offset losses, Valion Bio risks exhausting its cash runway before achieving critical milestones, potentially forcing dilutive financing at unfavorable terms.
Velocity Bioworks' ambition to evolve into a standalone, cash flow-positive CDMO faces substantial hurdles in a competitive outsourcing market dominated by established players with greater scale, broader service offerings, and deeper client relationships, making it uncertain whether the subsidiary can reliably attract and retain third-party biotech sponsors at scale. Although management targets the underserved Phase I and II manufacturing gap, Velocity Bioworks operates as a relatively new entrant with limited track record beyond internal use, and its San Antonio facility—while strategically located near defense ecosystems—may lack the geographic or technological differentiation needed to win long-term contracts against larger CDMOs with global footprints. The exclusive LarmorBio agreement, while promising, is tied to a single pre-revenue technology (BioScan-NMR) whose commercial success is unproven, and any delay in installation (targeted for July 2026) or failure to achieve broader market adoption could undermine the anticipated validation and revenue benefits. Until Velocity Bioworks demonstrates consistent third-party revenue growth, it remains a cost center rather than a profit driver, and the market may be overestimating its near-term financial contribution to the consolidated entity.
Valion Bio's expansion into oncology supportive care, while logically grounded in Entolimod's mechanism, faces significant commercial and clinical challenges that could delay or derail revenue generation, particularly given the crowded neutropenia market dominated by entrenched agents like Neupogen, Neulasta, and Leukine, which benefit from decades of clinical use, physician familiarity, and established reimbursement pathways. The company's plan to pursue physician-sponsored trials in 2026 introduces variability in trial design, site selection, and data quality, increasing the risk of inconsistent or underwhelming results that may not support Phase IIb readiness or regulatory advancement. Furthermore, the focus on extending the platform to Entolasta for longevity and immunosenescence indications introduces additional scientific uncertainty, as these areas lack validated biomarkers, clear regulatory pathways, and near-term commercial viability, potentially diverting resources from more immediate opportunities. Without near-term clinical milestones in oncology or clear differentiation in a well-served market, Valion Bio risks investing in long-term bets that may not materialize, while its cash position continues to erode under the weight of dual-program development without offsetting revenue.

Despite promising government engagement, Valion Bio remains heavily dependent on uncertain procurement outcomes from U.S. agencies like BARDA and the Department of War, with no guaranteed funding or contract in place for Entolimod's inclusion in the Strategic National Stockpile, exposing the company to significant execution risk if geopolitical priorities shift or competing countermeasures gain favor. While NIAID has funded a specific study protocol under the Animal Rule, this does not equate to a procurement commitment, and the path to BLA approval still hinges on favorable study results, successful tech transfer validation from Velocity Bioworks, and FDA acceptance—all of which carry inherent scientific and regulatory uncertainty. The company's financials underscore this vulnerability: operating expenses rose to $5.6 million in Q1 2026 from $1.4 million year-over-year, driven by Velocity Bioworks integration and rebranding costs, while cash reserves declined to $7.2 million from $12.6 million at year-end 2025, reflecting a burn rate that may not be sustainable without near-term non-dilutive inflows or additional financing. Without a secured government contract or meaningful CDMO revenue to offset losses, Valion Bio risks exhausting its cash runway before achieving critical milestones, potentially forcing dilutive financing at unfavorable terms.
Velocity Bioworks' ambition to evolve into a standalone, cash flow-positive CDMO faces substantial hurdles in a competitive outsourcing market dominated by established players with greater scale, broader service offerings, and deeper client relationships, making it uncertain whether the subsidiary can reliably attract and retain third-party biotech sponsors at scale. Although management targets the underserved Phase I and II manufacturing gap, Velocity Bioworks operates as a relatively new entrant with limited track record beyond internal use, and its San Antonio facility—while strategically located near defense ecosystems—may lack the geographic or technological differentiation needed to win long-term contracts against larger CDMOs with global footprints. The exclusive LarmorBio agreement, while promising, is tied to a single pre-revenue technology (BioScan-NMR) whose commercial success is unproven, and any delay in installation (targeted for July 2026) or failure to achieve broader market adoption could undermine the anticipated validation and revenue benefits. Until Velocity Bioworks demonstrates consistent third-party revenue growth, it remains a cost center rather than a profit driver, and the market may be overestimating its near-term financial contribution to the consolidated entity.
Valion Bio's expansion into oncology supportive care, while logically grounded in Entolimod's mechanism, faces significant commercial and clinical challenges that could delay or derail revenue generation, particularly given the crowded neutropenia market dominated by entrenched agents like Neupogen, Neulasta, and Leukine, which benefit from decades of clinical use, physician familiarity, and established reimbursement pathways. The company's plan to pursue physician-sponsored trials in 2026 introduces variability in trial design, site selection, and data quality, increasing the risk of inconsistent or underwhelming results that may not support Phase IIb readiness or regulatory advancement. Furthermore, the focus on extending the platform to Entolasta for longevity and immunosenescence indications introduces additional scientific uncertainty, as these areas lack validated biomarkers, clear regulatory pathways, and near-term commercial viability, potentially diverting resources from more immediate opportunities. Without near-term clinical milestones in oncology or clear differentiation in a well-served market, Valion Bio risks investing in long-term bets that may not materialize, while its cash position continues to erode under the weight of dual-program development without offsetting revenue.

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	206.44 Bn	23.61	5.42	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	179.97 Bn	-62.17	5.91	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	130.57 Bn	29.64	10.37	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	81.63 Bn	18.86	5.25	1.99 Bn
5	ARGX	Argenx Se	primary	60.34 Bn	35.18	11.55	-
6	MRNA	Moderna, Inc.	primary	54.37 Bn	-17.25	24.40	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	33.07 Bn	42.69	6.88	-
8	BIIB	Biogen Inc.	primary	31.84 Bn	38.15	3.17	8.09 Bn

Valion Bio VBIO

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password